logo
Share SHARE
FONT-SIZE Plus   Neg

Chelsea To Discuss NORTHERA NDA For Treatment Of Symptomatic Neurogenic OH

Chelsea Therapeutics International, Ltd. (CHTP) said it will meet with the Food and Drug Administration's, or FDA's, Cardiovascular and Renal Drugs Advisory Committee on February 23, 2012 to review clinical data in support of the New Drug Application, or NDA, for NORTHERA (droxidopa).

Chelsea is seeking approval of NORTHERA for treating symptomatic neurogenic orthostatic hypotension, or Neurogenic OH, in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

Dr. Simon Pedder, president and CEO of Chelsea, stated, "We have closely reviewed the materials prepared by the FDA, and look forward to presenting our clinical data to the Advisory Committee, which we believe will address the questions raised by the FDA. We believe that our clinical program has established robust safety and efficacy data for NORTHERA in this patient population."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Thursday after the markets closed that its second quarter profit fell 21% from last year, hurt by lower revenue and costs related to the planned separation of the company. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Accounting software maker Intuit reported a plunge in third-quarter profit, hurt by impairment charges, even as results topped Wall Street estimates, driven by growth in small business segment amid a strong tax season. Struggling teen-apparel retailer Aeropostale Inc. (ARO), Thursday said its first-quarter loss narrowed from a year ago, driven largely by stronger margins even as revenues continued to plunge dropped. Nevertheless, the company lost almost one-fifth of its market value in after-hours trade, with the...
comments powered by Disqus
Follow RTT